Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
telomeric antisense oligonucleotides
- Development stage
- Preclinical
- Lead developer
- TAG Therapeutics
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous, Subcutaneous
01
Overview
Telomeric antisense oligonucleotides (tASOs) are sequence-specific antisense oligonucleotides designed to target telomeric non-coding RNAs (tncRNAs), which are transcribed at dysfunctional or damaged telomeres. These tncRNAs are essential for recruiting DNA damage response (DDR) factors to damaged telomeres, thereby initiating and maintaining cellular senescence and chronic inflammation. By selectively binding to and silencing these tncRNAs, tASOs inhibit DDR activation at dysfunctional telomeres without altering telomere length. This therapeutic approach, originated by scientist Fabrizio d'Adda di Fagagna at IFOM and CNR, is being advanced clinically by spin-off TAG Therapeutics under the platform name TELOBLOCK. It has demonstrated preclinical efficacy in reversing cellular senescence, reducing inflammation, and restoring tissue homeostasis in models of idiopathic pulmonary fibrosis (IPF), Hutchinson-Gilford progeria syndrome (HGPS), aplastic anemia, and age-related hematopoietic decline.
- Brand names
- TELOBLOCK
- Other names
- tASOtASOstelomere-targeted antisense oligonucleotidestelomeric antisense oligonucleotide
Beyond the preview
Go deeper on telomeric antisense oligonucleotides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on telomeric antisense oligonucleotides.